BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 15973843)

  • 1. Hypersensitivity reactions to oxaliplatin: what nurses need to know.
    Bonosky K; Miller R
    Clin J Oncol Nurs; 2005 Jun; 9(3):325-30. PubMed ID: 15973843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of allergic reactions to oxaliplatin in colorectal cancer patients.
    Suenaga M; Mizunuma N; Shinozaki E; Matsusaka S; Chin K; Muto T; Konishi F; Hatake K
    J Support Oncol; 2008; 6(8):373-8. PubMed ID: 19149322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.
    Gammon D; Bhargava P; McCormick MJ
    Oncologist; 2004; 9(5):546-9. PubMed ID: 15477639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersensitivity reactions to oxaliplatin in two asian patients.
    Ng CV
    Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
    Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
    Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management.
    Hewitt MR; Sun W
    Clin Colorectal Cancer; 2006 Jul; 6(2):114-7. PubMed ID: 16945166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
    Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
    Nozawa H; Muto Y; Yamada Y
    Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
    Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
    Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin.
    Herrero T; Tornero P; Infante S; Fuentes V; Sánchez MN; De Barrio M; Baeza ML
    J Investig Allergol Clin Immunol; 2006; 16(5):327-30. PubMed ID: 17039675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches.
    Bano N; Najam R; Qazi F; Mateen A
    Asian Pac J Cancer Prev; 2016; 17(4):1637-41. PubMed ID: 27221832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersensitivity and idiosyncratic reactions to oxaliplatin.
    Thomas RR; Quinn MG; Schuler B; Grem JL
    Cancer; 2003 May; 97(9):2301-7. PubMed ID: 12712487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity reactions associated with oxaliplatin and their clinical management.
    Toki MI; Saif MW; Syrigos KN
    Expert Opin Drug Saf; 2014 Nov; 13(11):1545-54. PubMed ID: 25307143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin: practical guidelines for administration.
    Sorich J; Taubes B; Wagner A; Hochster H
    Clin J Oncol Nurs; 2004 Jun; 8(3):251-6. PubMed ID: 15208819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.
    Lee C; Gianos M; Klaustermeyer WB
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):179-87; quiz 187-9, 222. PubMed ID: 19354063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypersensitivity Reactions to oxaliplatin: incidence and management.
    Gowda A; Goel R; Berdzik J; Leichman CG; Javle M
    Oncology (Williston Park); 2004 Nov; 18(13):1671-5; discussion 1676, 1680, 1683-4. PubMed ID: 15648298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
    Park SJ; Lee KY; Park WS; Min SY
    Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.
    Mori Y; Nishimura T; Kitano T; Yoshimura K; Matsumoto S; Kanai M; Hazama M; Ishiguro H; Nagayama S; Yanagihara K; Teramukai S; Chiba T; Sakai Y; Fukushima M
    Oncology; 2010; 79(1-2):136-43. PubMed ID: 21150228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin hypersensitivity: case report and successful repeat desensitization.
    Edmondson DA; Gruling BJ; Urmanski AM; Wong SJ; Levy MB
    Am J Ther; 2007; 14(1):116-8. PubMed ID: 17303980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful desensitization to oxaliplatin.
    Mis L; Fernando NH; Hurwitz HI; Morse MA
    Ann Pharmacother; 2005 May; 39(5):966-9. PubMed ID: 15784807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.